16.97
-0.45
(-2.58%)
At close: January 31 at 4:00:01 PM EST
17.49
+0.52
+(3.06%)
After hours: January 31 at 6:40:11 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 5 | 8 | 8 |
| Avg. Estimate | -0.45 | -0.23 | -2.34 | -1.48 |
| Low Estimate | -1.24 | -0.69 | -3.11 | -5.15 |
| High Estimate | 0.59 | 0 | -1.29 | 3.12 |
| Year Ago EPS | -0.32 | -1 | 0.28 | -2.34 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 6 | 11 | 11 |
| Avg. Estimate | 44.64M | 56.24M | 174.23M | 205.13M |
| Low Estimate | 10M | 20.4M | 139.5M | 90.6M |
| High Estimate | 91.58M | 76.39M | 221.13M | 509.95M |
| Year Ago Sales | 33.99M | 38.01M | 169.93M | 174.23M |
| Sales Growth (year/est) | 31.34% | 47.95% | 2.53% | 17.74% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.05 | -1.14 | -1.57 | -1.02 |
| EPS Actual | -0.32 | -1 | -0.64 | -0.26 |
| Difference | 0.73 | 0.14 | 0.93 | 0.76 |
| Surprise % | 69.62% | 12.59% | 59.23% | 74.60% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.45 | -0.23 | -2.34 | -1.48 |
| 7 Days Ago | -0.45 | -0.23 | -2.34 | -1.48 |
| 30 Days Ago | -0.51 | -0.27 | -2.39 | -1.48 |
| 60 Days Ago | -0.51 | -0.27 | -2.39 | -1.48 |
| 90 Days Ago | -0.37 | -0.48 | -3.01 | -1.54 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 1 | 1 |
| Up Last 30 Days | 1 | 2 | 1 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 5 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ARCT | -40.96% | 76.80% | -944.97% | 36.53% |
| S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/13/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/7/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/17/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 12/16/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/8/2024 |
| Initiated | Leerink Partners: Outperform | 8/12/2024 |
Related Tickers
ADCT ADC Therapeutics SA
1.6800
-2.33%
NTLA Intellia Therapeutics, Inc.
10.32
-1.81%
IONS Ionis Pharmaceuticals, Inc.
31.90
-4.26%
MIRM Mirum Pharmaceuticals, Inc.
48.88
+0.91%
BEAM Beam Therapeutics Inc.
25.92
-4.99%
EDIT Editas Medicine, Inc.
1.3100
-4.38%
FDMT 4D Molecular Therapeutics, Inc.
5.60
0.00%
HRMY Harmony Biosciences Holdings, Inc.
38.77
-1.95%
DNLI Denali Therapeutics Inc.
23.30
-1.19%
STOK Stoke Therapeutics, Inc.
11.48
+4.46%